Molecular Partners AG (MOLN) Stock Forecast
MOLN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 5 analysts
- Price target
- $10.49 average of analyst targets
- Upside to target
- +194.7% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $-0.46
- 52-week range
- $3.54 – $5.12
MOLN analyst ratings
5 analystsNumber of analysts at each rating.
MOLN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MOLN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.34 | −$0.34 | −$0.34 | −$0.33 | −3.0% | 1 |
| Current fiscal year (2026) | −$1.11 | −$1.46 | −$0.65 | −$1.65 | +32.7% | 3 |
| Next fiscal year (2027) | −$0.14 | −$1.33 | $1.81 | −$1.11 | +87.8% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MOLN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $5.6M | $0 | $22.3M | 0.0% | 4 |
| Next fiscal year (2027) | $30.7M | $0 | $122.8M | +450.0% | 4 |
MOLN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MOLN revenue: reported and forecast
MOLN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.34 | −$0.34 | −$0.35 | −$0.35 | −$0.34 | 0.0% | 0 up · 0 down |
| Current fiscal year (2026) | −$1.15 | −$1.15 | −$1.16 | −$1.16 | −$1.11 | −3.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.22 | −$0.22 | −$0.21 | −$0.21 | −$0.14 | −37.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MOLN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MOLN beat in 7 of 12.
What analysts expect from MOLN
5 analysts cover Molecular Partners; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.49, 194.7% above the latest close of $3.56. Analysts expect earnings of −$1.11 per share for 2026, +32.7% from a year earlier. For 2027 the average estimate is −$0.14 per share on revenue of $30.7 million. Molecular Partners beat the EPS estimate in 7 of the last 12 quarters.
Related: MOLN income statement, MOLN key metrics, MOLN chart. See the MOLN stock overview for the latest quote and news.
MOLN forecast FAQ
What is Molecular Partners's price target?
The average analyst price target for Molecular Partners is $10.49, 194.7% above the latest close of $3.56.
Is Molecular Partners a buy, hold or sell?
Of 5 analysts covering Molecular Partners, 4 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Molecular Partners's EPS forecast?
Analysts forecast −$1.11 per share for 2026 (range −$1.46 to −$0.65); for 2027 the estimate is −$0.14.
What is Molecular Partners's revenue forecast?
The average revenue estimate for 2026 is $5.6 million, growth of 0.0%; for 2027 it is $30.7 million.
When does Molecular Partners report earnings?
Molecular Partners is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 before the market opens; the EPS estimate is $-0.46.
Does Molecular Partners usually beat earnings estimates?
Molecular Partners reported EPS at or above the analyst estimate in 7 of the last 12 quarters.